Clinical characteristics of 105 patients with ALCL
| Characteristic . | ALCL stratified by ALK status, N (%) . | ALK-negative ALCL stratified by genetics, N (%) . | All ALCL, N (%) . | |||
|---|---|---|---|---|---|---|
| ALK positive (N = 32) . | ALK negative (N = 73) . | DUSP22 (N = 22) . | TP63 (N = 6) . | −/−/− (N = 45) . | Total (N = 105) . | |
| Age | ||||||
| Median | 27.5 | 58 | 53.5 | 48 | 62 | 51 |
| Range | 6-77 | 22-94 | 36-76 | 30-73 | 22-94 | 6-94 |
| Gender | ||||||
| Female | 11 (34) | 24 (33) | 7 (32) | 3 (50) | 14 (31) | 35 (33) |
| Male | 21 (66) | 49 (67) | 15 (68) | 3 (50) | 31 (69) | 70 (67) |
| Ann Arbor stage | ||||||
| I | 7 (26) | 4 (11) | 0 (0) | 0 (0) | 4 (17) | 11 (17) |
| II | 6 (22) | 5 (14) | 1 (14) | 1 (20) | 3 (12) | 11 (17) |
| III | 0 (0) | 7 (19) | 2 (28) | 1 (20) | 4 (17) | 7 (11) |
| IV | 14 (52) | 20 (56) | 4 (57) | 3 (60) | 13 (54) | 34 (54) |
| Missing | 5 | 37 | 15 | 1 | 21 | 42 |
| IPI | ||||||
| 0-1 | 20 (69) | 21 (40) | 6 (43) | 2 (33) | 13 (41) | 41 (50) |
| 2 | 6 (21) | 15 (29) | 2 (14) | 3 (50) | 10 (31) | 21 (26) |
| 3 | 3 (10) | 9 (17) | 3 (21) | 1 (17) | 5 (16) | 12 (15) |
| 4-5 | 0 (0) | 7 (14) | 3 (21) | 0 (0) | 4 (12) | 7 (9) |
| Missing | 3 | 21 | 8 | 0 | 13 | 24 |
| Extranodal involvement at diagnosis | ||||||
| Yes | 18 (56) | 30 (44) | 7 (33) | 2 (33) | 21 (49) | 48 (48) |
| No | 14 (44) | 38 (56) | 14 (67) | 4 (67) | 20 (51) | 52 (52) |
| Missing | 0 | 5 | 1 | 0 | 4 | 5 |
| Skin involvement during disease course | ||||||
| Yes | 4 (13) | 14 (22) | 5 (28) | 2 (33) | 7 (17) | 18 (19) |
| No | 26 (87) | 50 (78) | 13 (72) | 4 (67) | 33 (83) | 76 (81) |
| Missing | 2 | 9 | 4 | 0 | 5 | 11 |
| Initial treatment | ||||||
| CHOP/CHOP-like | 22 (76) | 51 (78) | 18 (90) | 5 (83) | 28 (72) | 73 (78) |
| RT only | 1 (3) | 5 (8) | 0 (0) | 0 (0) | 5 (13) | 6 (6) |
| Other | 6 (21) | 5 (8) | 1 (5) | 0 (0) | 4 (10) | 11 (12) |
| None | 0 (0) | 4 (6) | 1 (5) | 1 (17) | 2 (5) | 4 (4) |
| Missing/unknown | 3 | 8 | 2 | 0 | 6 | 11 |
| Stem cell transplant | ||||||
| No | 22 (79) | 55 (86) | 15 (79) | 5 (83) | 35 (90) | 77 (84) |
| Yes | 6 (21) | 9 (14) | 4 (21) | 1 (17) | 4 (10) | 15 (16) |
| Consolidative | 1 (4) | 2 (3) | 1 (5) | 0 (0) | 1 (3) | 3 (3) |
| Salvage | 4 (14) | 4 (6) | 2 (11) | 1 (17) | 1 (3) | 8 (9) |
| Unknown timing | 1 (4) | 3 (5) | 1 (5) | 0 (0) | 2 (5) | 4 (4) |
| Missing | 4 | 9 | 3 | 0 | 6 | 13 |
| Characteristic . | ALCL stratified by ALK status, N (%) . | ALK-negative ALCL stratified by genetics, N (%) . | All ALCL, N (%) . | |||
|---|---|---|---|---|---|---|
| ALK positive (N = 32) . | ALK negative (N = 73) . | DUSP22 (N = 22) . | TP63 (N = 6) . | −/−/− (N = 45) . | Total (N = 105) . | |
| Age | ||||||
| Median | 27.5 | 58 | 53.5 | 48 | 62 | 51 |
| Range | 6-77 | 22-94 | 36-76 | 30-73 | 22-94 | 6-94 |
| Gender | ||||||
| Female | 11 (34) | 24 (33) | 7 (32) | 3 (50) | 14 (31) | 35 (33) |
| Male | 21 (66) | 49 (67) | 15 (68) | 3 (50) | 31 (69) | 70 (67) |
| Ann Arbor stage | ||||||
| I | 7 (26) | 4 (11) | 0 (0) | 0 (0) | 4 (17) | 11 (17) |
| II | 6 (22) | 5 (14) | 1 (14) | 1 (20) | 3 (12) | 11 (17) |
| III | 0 (0) | 7 (19) | 2 (28) | 1 (20) | 4 (17) | 7 (11) |
| IV | 14 (52) | 20 (56) | 4 (57) | 3 (60) | 13 (54) | 34 (54) |
| Missing | 5 | 37 | 15 | 1 | 21 | 42 |
| IPI | ||||||
| 0-1 | 20 (69) | 21 (40) | 6 (43) | 2 (33) | 13 (41) | 41 (50) |
| 2 | 6 (21) | 15 (29) | 2 (14) | 3 (50) | 10 (31) | 21 (26) |
| 3 | 3 (10) | 9 (17) | 3 (21) | 1 (17) | 5 (16) | 12 (15) |
| 4-5 | 0 (0) | 7 (14) | 3 (21) | 0 (0) | 4 (12) | 7 (9) |
| Missing | 3 | 21 | 8 | 0 | 13 | 24 |
| Extranodal involvement at diagnosis | ||||||
| Yes | 18 (56) | 30 (44) | 7 (33) | 2 (33) | 21 (49) | 48 (48) |
| No | 14 (44) | 38 (56) | 14 (67) | 4 (67) | 20 (51) | 52 (52) |
| Missing | 0 | 5 | 1 | 0 | 4 | 5 |
| Skin involvement during disease course | ||||||
| Yes | 4 (13) | 14 (22) | 5 (28) | 2 (33) | 7 (17) | 18 (19) |
| No | 26 (87) | 50 (78) | 13 (72) | 4 (67) | 33 (83) | 76 (81) |
| Missing | 2 | 9 | 4 | 0 | 5 | 11 |
| Initial treatment | ||||||
| CHOP/CHOP-like | 22 (76) | 51 (78) | 18 (90) | 5 (83) | 28 (72) | 73 (78) |
| RT only | 1 (3) | 5 (8) | 0 (0) | 0 (0) | 5 (13) | 6 (6) |
| Other | 6 (21) | 5 (8) | 1 (5) | 0 (0) | 4 (10) | 11 (12) |
| None | 0 (0) | 4 (6) | 1 (5) | 1 (17) | 2 (5) | 4 (4) |
| Missing/unknown | 3 | 8 | 2 | 0 | 6 | 11 |
| Stem cell transplant | ||||||
| No | 22 (79) | 55 (86) | 15 (79) | 5 (83) | 35 (90) | 77 (84) |
| Yes | 6 (21) | 9 (14) | 4 (21) | 1 (17) | 4 (10) | 15 (16) |
| Consolidative | 1 (4) | 2 (3) | 1 (5) | 0 (0) | 1 (3) | 3 (3) |
| Salvage | 4 (14) | 4 (6) | 2 (11) | 1 (17) | 1 (3) | 8 (9) |
| Unknown timing | 1 (4) | 3 (5) | 1 (5) | 0 (0) | 2 (5) | 4 (4) |
| Missing | 4 | 9 | 3 | 0 | 6 | 13 |
RT, radiotherapy; −/−/−, triple-negative ALCL.